The Fund Grade · free · no account needed
What grade does FPHAX get?
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-10-01
Fidelity Select Pharmaceuticals
#132 of 500 graded active funds · blend · large segment peer group
The point · specialist footprint
FPHAX puts more of its book behind proven specialists than 81% of graded funds.
Bottom 20%
Bottom 40%
Middle
Top 40%
● Top 20%
That has mattered: over the past 2.7 years, funds on this rung beat bottom-rung funds by about 3.8% per quarter, and beat the S&P in 43% of fund-quarters versus their 22%. The evidence argues this fund earns its seat.
10,000+ funds tracked · the graded specialists among them drive every read
The grade scores this fund's specialist share, the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
FPHAX vs the Honor Roll · share card ↗Conviction exposure
45.5%
of the book in specialist-converged names
Late-stage weight
21.7%
of the book in Crowded or Fading names
Active share
98.2%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book: top names by stage · as of 2026-10-20
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
FPHAX earns a B grade with specialists making up 45.5% of the book, which is meaningful backing. The early conviction calls on VTRS, MRK, and JNJ are the bright spot, but GSK at 8% of the fund is fading, and that is a large position to have specialists walking away from.
→ Watch GSK closely, it carries an 8% weight and specialists are actively leaving that position.
→ Fidelity has higher graded funds in the same family worth comparing against this B grade.
Support leaving these positions
Same family, higher grade
Read from today's disclosed book. Evidence, not advice.